Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE 2: Eptinezumab in chronic migraine
NCT02974153Phase 3Completed
- Sponsor
- Alder Biopharmaceuticals
- Start
- Nov 2016
- Primary completion
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of eptinezumab in chronic migraine, sponsored by Alder Biopharmaceuticals. Started Nov 2016; status: completed.
02
Drugs
eptinezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT02974153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974153.